Non-Small Cell Lung Cancer (NSCLC) | Topics

 
Roy S. Herbst, MD, PhD, on What Multidisciplinary Providers Should Know About KEYNOTE-010
February 26, 2021

The KEYNOTE-010 study evaluated the use of either pembrolizumab or docetaxel in patients with previously treated, PD-L1–positive advanced non–small cell lung cancer.

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study
February 24, 2021

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.

First-Line Nivolumab/Ipilimumab and 2 Chemo Cycles Provide Superior OS Vs Chemo Alone in Advanced NSCLC
February 23, 2021

According to investigators on the CheckMate 9LA trial, these data support the use of nivolumab plus ipilimumab and 2 cycles of chemotherapy as a new first-line treatment for patients with advanced non–small cell lung cancer, regardless of PD-L1 expression or histology.